Skip to Content

Find Comparable ETFs for SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI - PCX
ETF Category
Health & Biotech Equities
Asset Class
Equity
AUM
$7,837M
Expense Ratio
0.35% (Very Low)
Trading Volume
7.2M (High)
Issuer
State Street
Number of Holdings
140
Inception Date
2006-01-31 (19 years)
Momentum
Very Weak Weak Very Strong
AUM
Micro Medium Very Large
Concentration
Very Low Low Very High
Volatility
Very Low High Very High
Overview
Momentum
Concentration
ESG
P/E Ratio
17.88
Annual Dividend Rate
0.13%
Beta
0.97
50-Day Moving Average
$90.74
Price vs. 50-Day MA
-4.31%
200-Day Moving Average
$95.25
Price vs. 200-Day MA
-8.84%
1 Year Fund Flow
$133M (2% of AUM)
3 Year Fund Flow
$2,495M (32% of AUM)
5 Year Fund Flow
$3,332M (43% of AUM)
% in Top 10 Holdings (Market Cap Weighted)
27.25%
% in Top 15 Holdings (Market Cap Weighted)
39.23%
% in Top 50 Holdings (Market Cap Weighted)
74.72%
ESG Score
5.4800
ESG Peer %
23.50
ESG Global %
29.39
Carbon Intensity (Tons CO2e/$M Sales)
37
ESG Exclusion %
0.00
Sustainable Impact %
29.00

First Trust NYSE Arca Biotechnology Index Fund

FBT - PCX
View FBT's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $1,178M
Expense Ratio: 0.56% (Moderate)
Volume: 28.0K (Low)
Issuer: First Trust
Holdings: 31
Inception: 2006-06-19 (18 years)
Neutral Momentum
Medium AUM
High Concentration
Low Volatility
Compare
Overview
Momentum
Concent.
ESG

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 85%

R-squared: 73%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 6
  • FBT in XBI's comparables: Yes
  • XBI in FBT's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

valuation
A+

valuation

Compares valuation metrics to assess if the assets are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 17.55 vs 17.88

A high score indicates that the market values these assets similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • FBT Beta: 0.79 (Low)
  • XBI Beta: 0.97 (Average)
  • FBT 200-day Volatility: 14.96%
  • XBI 200-day Volatility: 23.88%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • FBT Price vs 200-day MA: 104%
  • XBI Price vs 200-day MA: 91%

Performance Comparison:

Period FBT XBI
Year_1 9% 19%
Year_3 0% -8%
Year_5 4% 2%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: PCX vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • FBT Dividend Yield: 0%
  • XBI Dividend Yield: 0%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
17.55
Annual Dividend Rate
0.00%
Beta
0.79
50-Day Moving Average
$174.15
Price vs. 50-Day MA
-0.39%
200-Day Moving Average
$167.51
Price vs. 200-Day MA
3.56%
1 Year Fund Flow
-$306M (-26% of AUM)
3 Year Fund Flow
-$646M (-55% of AUM)
5 Year Fund Flow
-$1,855M (-158% of AUM)
% in Top 10 Holdings
37%
% in Top 15 Holdings
53%
% in Top 50 Holdings
100%
ESG Score
6.1300
ESG Peer %
37.59
ESG Global %
40.26
Carbon Intensity
28
ESG Exclusion %
0.00
Sustainable Impact %
40.27

ALPS Medical Breakthroughs ETF

SBIO - PCX
View SBIO's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $116M
Expense Ratio: 0.50% (Moderate)
Volume: 11.6K (Low)
Issuer: SS&C
Holdings: 102
Inception: 2014-12-30 (10 years)
Weak Momentum
Small AUM
Very High Concentration
High Volatility
Compare
Overview
Momentum
Concent.
ESG

The SPDR S&P Biotech ETF focuses on biotechnology companies, much like SBIO, and offers exposure to innovative medical breakthroughs and therapies.

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 91%

R-squared: 82%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • SBIO in XBI's comparables: No
  • XBI in SBIO's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • SBIO Beta: 0.92 (Average)
  • XBI Beta: 0.97 (Average)
  • SBIO 200-day Volatility: 27.48%
  • XBI 200-day Volatility: 23.88%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • SBIO Price vs 200-day MA: 86%
  • XBI Price vs 200-day MA: 91%

Performance Comparison:

Period SBIO XBI
Year_1 14% 19%
Year_3 -7% -8%
Year_5 0% 2%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: PCX vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • SBIO Dividend Yield: -1%
  • XBI Dividend Yield: 0%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
N/A
Annual Dividend Rate
0.19%
Beta
0.92
50-Day Moving Average
$32.36
Price vs. 50-Day MA
-5.04%
200-Day Moving Average
$35.54
Price vs. 200-Day MA
-13.53%
1 Year Fund Flow
-$9M (-8% of AUM)
3 Year Fund Flow
-$53M (-46% of AUM)
5 Year Fund Flow
-$58M (-50% of AUM)
% in Top 10 Holdings
27%
% in Top 15 Holdings
38%
% in Top 50 Holdings
80%
ESG Score
5.3000
ESG Peer %
21.43
ESG Global %
27.18
Carbon Intensity
52
ESG Exclusion %
0.00
Sustainable Impact %
8.43

Vanguard Health Care Index Fund ETF Shares

VHT - PCX
View VHT's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $18,155M
Expense Ratio: 0.09% (Very Low)
Volume: 143.3K (Moderate)
Issuer: Vanguard
Holdings: 419
Inception: 2004-01-26 (21 years)
Neutral Momentum
Large AUM
Very Low Concentration
Low Volatility
Compare
Overview
Momentum
Concent.
ESG

The SPDR S&P Biotech ETF focuses specifically on the biotechnology industry, providing a more niche comparison to VHT’s broader health care offerings.

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 69%

R-squared: 47%

This indicates a moderate positive relationship between the price movements of these assets.

network
A

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 0
  • VHT in XBI's comparables: No
  • XBI in VHT's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

valuation
A+

valuation

Compares valuation metrics to assess if the assets are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 22.00 vs 17.88

A high score indicates that the market values these assets similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

volatility
A-

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • VHT Beta: 0.73 (Low)
  • XBI Beta: 0.97 (Average)
  • VHT 200-day Volatility: 10.58%
  • XBI 200-day Volatility: 23.88%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • VHT Price vs 200-day MA: 100%
  • XBI Price vs 200-day MA: 91%

Performance Comparison:

Period VHT XBI
Year_1 15% 19%
Year_3 4% -8%
Year_5 11% 2%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: PCX vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • VHT Dividend Yield: 1%
  • XBI Dividend Yield: 0%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
22.00
Annual Dividend Rate
1.28%
Beta
0.73
50-Day Moving Average
$264.61
Price vs. 50-Day MA
2.28%
200-Day Moving Average
$271.01
Price vs. 200-Day MA
-0.14%
1 Year Fund Flow
-$853M (-5% of AUM)
3 Year Fund Flow
$751M (4% of AUM)
5 Year Fund Flow
$3,074M (17% of AUM)
% in Top 10 Holdings
48%
% in Top 15 Holdings
59%
% in Top 50 Holdings
86%
ESG Score
6.5900
ESG Peer %
54.32
ESG Global %
52.52
Carbon Intensity
15
ESG Exclusion %
0.02
Sustainable Impact %
10.85
Toggle between similar ETFs and stocks for comparison.

Loading comparable ETFs ...

First Trust NYSE Arca Biotechnology Index Fund

FBT - PCX
A+
$173.47 -0.91 (-0.52%)
Health & Biotech Equities
Equity
AUM: $1,178M
Expense Ratio: 0.56% (Moderate)
Volume: 28.0K (Low)
Issuer: First Trust
Holdings: 31
Inception: 2006-06-19 (18 years)
Neutral Momentum
Medium AUM
High Concentration
Low Volatility

ALPS Medical Breakthroughs ETF

SBIO - PCX
A+
$30.73 -0.10 (-0.32%)
Health & Biotech Equities
Equity
AUM: $116M
Expense Ratio: 0.50% (Moderate)
Volume: 11.6K (Low)
Issuer: SS&C
Holdings: 102
Inception: 2014-12-30 (10 years)
Weak Momentum
Small AUM
Very High Concentration
High Volatility

Vanguard Health Care Index Fund ETF Shares

VHT - PCX
A+
$270.64 -1.73 (-0.63%)
Health & Biotech Equities
Equity
AUM: $18,155M
Expense Ratio: 0.09% (Very Low)
Volume: 143.3K (Moderate)
Issuer: Vanguard
Holdings: 419
Inception: 2004-01-26 (21 years)
Neutral Momentum
Large AUM
Very Low Concentration
Low Volatility